Scedosporium is an important pathogen in cystic fibrosis (CF) and post-transplantation, but it rarely causes invasive infection. Treatment remains challenging, particularly due to the inherent resistance to multiple antifungal agents. We present 3 complicated invasive tracheobronchial and lung Scedosporium apiospermum infections following lung transplantation. In 2 of 3 cases, the infection was clinically and radiologically cured with frequent cleansing bronchoscopies, combining triazole with terbinafine therapy and nebulized posaconazole. These cases highlight the importance of adjunctive nebulized therapy in addition to prolonged triazole treatment to manage complex invasive Scedosporium infections in immunosuppressed patients. Posaconazole (PSZ) was delivered during the bronchoscopy procedure through intrabronchial administration, whereas an eFlow rapid ® device was used for nebulized therapy. Topical posaconazole was well tolerated in 2 patients, with only a slight cough during administrations; the third patient had local irritation with poor tolerance, which led to its withdrawal. This is the first report on compassionate use of topical PSZ as salvage therapy for resistant mold infections in lung transplant recipients. These 3 cases represent the entire experience using this approach; no additional patients have received this therapy due to there not having been any additional cases of Scedosporium tracheobronchitis presented.
Scedosporium is an important pathogen in cystic fibrosis (CF) and post-transplantation, but it rarely causes invasive infection. Treatment remains challenging, particularly due to the inherent resistance to multiple antifungal agents. We present 3 complicated invasive tracheobronchial and lung Scedosporium apiospermum infections following lung transplantation. In 2 of 3 cases, the infection was clinically and radiologically cured with frequent cleansing bronchoscopies, combining triazole with terbinafine therapy and nebulized posaconazole. These cases highlight the importance of adjunctive nebulized therapy in addition to prolonged triazole treatment to manage complex invasive Scedosporium infections in immunosuppressed patients. Posaconazole (PSZ) was delivered during the bronchoscopy procedure through intrabronchial administration, whereas an eFlow rapid ® device was used for nebulized therapy. Topical posaconazole was well tolerated in 2 patients, with only a slight cough during administrations; the third patient had local irritation with poor tolerance, which led to its withdrawal.
This is the first report on compassionate use of topical PSZ as salvage therapy for resistant mold infections in lung transplant recipients. These 3 cases represent the entire experience using this approach; no additional patients have received this therapy due to there not having been any additional cases of Scedosporium tracheobronchitis presented.
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| INTRODUCTION

Invasive fungal infections (IFIs) after lung transplantation (LT) occur
in from 3% to 14% 1 of recipients, mainly due to Aspergillus fumigatus, with an overall mortality rate of nearly 22%. Emerging molds like
Scedosporium apiospermum complex and Lomentospora prolificans (formerly Scedosporium prolificans) are a major concern due to the high rate of dissemination and poor outcomes. These molds are particularly known for their high rate of therapeutic failures and relapse. In particular, L. prolificans represents a pan-antifungal-resistant species with mortality rates of up to 95% in immunocompromised patients. We present 3 cases in which life-threatening invasive lung infection by Scedosporium apiospermum complex was treated with standard antifungal drugs plus inhaled posaconazole as salvage therapy due to poor clinical evolution, despite correct antifungal systemic therapy; in all cases, plasma antifungal levels were in the recommended range.
All cases had tracheobronchial/anastomotic and pulmonary invasive infection according to standardized definitions. 11 Our team used posaconazole because of our index patient, who presented a serious adverse event with voriconazole pretransplant and who was allergic to AmB.
As a last therapeutic option, inhaled posaconazole was administered, along with conventional routes of administration, in a critical situation, and providentially achieved good results. Based on our limited experience, posaconazole is suitable to be inhaled and has a beneficial effect for complicated invasive pulmonary scedosporiosis.
| CASE DESCRIPTIONS
We report the successful treatment of 3 aggressive invasive tracheobronchial and pulmonary infections caused by S. apiospermum complex after bilateral LT, adding topical posaconazole (aerosolized and/ or intrabronchial instillation) to conventional treatment. Prior to the addition of topical posaconazole, all the patients had a poor evolution, despite combined antifungal therapy (Table 1) .
Patients' demographic characteristics, underlying disease, onset of IFI, post-LT prophylaxis, treatment, and outcome are detailed in Table 1 . In all patients, the level of immunosuppression was opti- 
| Patient A
A 37-year-old woman diagnosed with underlying cystic fibrosis who 
| Patient B
A 59-year-old man with emphysema underwent bilateral lung trans- asymptomatic CMV infection. S. apiospermum was isolated from BAL at 31 POD. We started with intravenous posaconazole 300 mg/day (plasma levels 1.15 mg/L). After several positive endobronchial biopsies, L-AmB was added to systemic therapy at 86 POD and terbinafine at 102 POD (see Table 1 
| PERMISSIONS AND MODUS OPERANDI
Hospital approval and informed consent were obtained from all pa- 
A B
deoxycholate using a variety of dosing regimens; others, using aerosolized AmB lipid formulations or inhaled voriconazole. One main drawback for these inhaled therapies is the lack of rigorous pharmacokinetic studies to determine the appropriate dose or delivery method and long-term outcome.
This is the first report of compassionate use of topical posaconazole as salvage therapy for resistant mold infections in LT recipients.
A favorable outcome was achieved in 2 of 3 patients. Unfortunately, by chance or due to a cross-infection, we had 3 cases of aggressive pulmonary Scedosporium infections in the same year.
Regarding posaconazole trough levels, therapeutic success has been associated with levels >0.5 mg/L in cardiothoracic transplant recipients. 17 In our 3 patients, the levels were between >1.0 and 1.25 mg/L; however, we did not achieve therapeutic response, and we used topical posaconazole as a last therapeutic option. Although it is a therapy without any scientific evidence thus far, our favorable results have motivated us to present them to the scientific community.
| CONCLUSION
In our experience, topical posaconazole has characteristics that make it suitable for inhalation, shows tolerability similar to that of other nebulized antifungal drugs, is effective, and could be used if the patient does not progress adequately with conventional treatment or if the infection is due to highly resistant molds. It is important to emphasize that levels of antifungal drugs should be available during treatment in all cases of IFI. 18 Topical delivery could be an option for treatment of patients in selected cases, but clinical trials and more experience is required.
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